Friends of Cancer Research is our country's leading voice in advocating for policies and solutions that will get treatments to patients in the safest and quickest way posible.
Friends of Cancer Research's 2013 Annual Report is now available for download.
Since President Obama signed the Breakthrough Therapy designation into law as part of the Food and Drug Administration Safety and Innovation Act, there have already been nine designations announced.
Friends Honors Governor Martin O'Malley, Governor Bob McDonnell, and philanthropist Sherry Lansing
Patients, drug developers, and regulators discussed Breakthrough Therapy's progress at our May briefing
Researchers, drug developers, and patient advocates share their thoughts about Lung-MAP
Eylea (aflibercept) - (Regeneron)
for the treatment of diabetic retinopathy
Nuplazid (Pimavanserin) - (Acadia)
for the treatment of Parkinson's disease psychosis
CRS-207 - (Aduro)
in combination with GVAX for the treatment of pancreatic cancer
Leaders from advocacy, industry and government share their thoughts on the impact of Lung-MAP, a recently launched innovative clinical trial for lung cancer.
"There isn't a day where I'm not overwhelmed by how many people are dealing with this disease, and that's what drives all of our work at Friends of Cancer Research."
FRIENDS OF CANCER RESEARCH1800 M Street NW Suite 1050 | Washington, DC 20036202.944.6700